| Literature DB >> 28173819 |
Tarique Al Musa1, Akhlaque Uddin1, Peter P Swoboda1, Timothy A Fairbairn1, Laura E Dobson1, Anvesha Singh2, Pankaj Garg1, Christopher D Steadman2, Bara Erhayiem1, Ananth Kidambi1, David P Ripley1, Adam K McDiarmid1, Philip Haaf1, Daniel J Blackman3, Sven Plein1,3, Gerald P McCann2, John P Greenwood4,5.
Abstract
BACKGROUND: It is unknown whether circumferential strain is associated with prognosis after treatment of aortic stenosis (AS). We aimed to characterise strain in severe AS, using myocardial tagging cardiovascular magnetic resonance (CMR), prior to and following Transcatheter Aortic Valve Implantation (TAVI) and Surgical Aortic Valve Replacement (SAVR), and determine whether abnormalities in strain were associated with outcome.Entities:
Keywords: Aortic stenosis; Aortic valve replacement; Myocardial tissue tagging; Transcatheter aortic valve implantation
Mesh:
Year: 2017 PMID: 28173819 PMCID: PMC5297161 DOI: 10.1186/s12968-017-0329-7
Source DB: PubMed Journal: J Cardiovasc Magn Reson ISSN: 1097-6647 Impact factor: 5.364
Fig. 1Study Profile
Patient characteristics and baseline echocardiographic data
| Characteristics | SAVR (n = 46) | TAVI (n = 52) | p Value* |
|---|---|---|---|
| Age | 73.0 ± 7.0 | 80.9 ± 6.4 | <0.001 |
| Male gender, n (%) | 34 (74) | 28 (54) | 0.041 |
| STS Mortality (%) | 2.06 ± 0.6 | 6.03 ± 3.4 | <0.001 |
| BMI (kgm−2) | 27.5 ± 4.4 | 27.0 ± 3.8 | 0.709 |
| Previous MI, n (%) | 6 (13) | 9 (17) | 0.560 |
| Previous PCI, n (%) | 1 (2) | 14 (27) | 0.001 |
| Previous CABG, n (%) | 1 (2) | 17 (33) | <0.001 |
| Stroke/TIA, n (%) | 6 (13) | 8 (15) | 0.742 |
| Peripheral vascular disease, n (%) | 1 (2) | 10 (19) | 0.008 |
| Hypertension | 32 (70) | 25 (48) | 0.032 |
| Diabetes Mellitus, n (%) | 7 (15) | 10 (19) | 0.602 |
| Hyperlipidaemia, n (%) | 23 (50) | 31 (60) | 0.342 |
| COPD, n (%) | 4 (9) | 12 (23) | 0.056 |
| Atrial Fibrillation, n (%) | 3 (7) | 15 (29) | 0.005 |
| eGFR (ml/min/1.73 m2) | 73.3 ± 13.8 | 59.8 ± 18.9 | <0.001 |
| AVA (cm2) | 0.83 ± 0..46 | 0.59 ± 0.17 | <0.001 |
| Mean aortic valve PG (mmHg) | 46.9 ± 13.4 | 53.2 ± 19.2 | 0.102 |
| Pulmonary Hypertensiona, n (%) | 7 (15) | 15 (29) | 0.110 |
| ValvuloArterial Impedance (Zva) | 3.73 ± 0.99 | 3.71 ± 1.09 | 0.734 |
Values are mean ± SD or n(%)
AVA aortic valve area, CABG coronary artery bypass grafting, eGFR estimated glomerular filtration rate, COPD chronic obstructive pulmonary disease, MI myocardial infarction, MPG mean pressure gradient, NYHA New York Health Association, PCI percutaneous coronary intervention, Zva valvuloarterial impedance (systolic arterial pressure + mean transvalvular gradient/stroke volume index)
*p Value for comparison between TAVI and SAVR groups
aPulmonary hypertension defined as estimated pulmonary artery systolic pressure by transthoracic echocardiography to be >35 mmHg
Preoperative baseline measurements and postoperative changes in the separate procedural groups
| SAVR | TAVI | p Value† | |||
|---|---|---|---|---|---|
| Baseline | 6 months | Baseline | 6 months | ||
| Haemodynamics | |||||
| Heart Rate (bpm) | 63 ± 9 | 64 ± 12 | 67 ± 12 | 68 ± 15 | 0.952 |
| Systolic BP (mmHg) | 136 ± 21 | 133 ± 20 | 133 ± 25 | 137 ± 23 | 0.200 |
| Diastolic BP (mmHg) | 75 ± 10 | 72 ± 11 | 66 ± 10 | 65 ± 9 | 0.265 |
| Valvular Function | |||||
| Aortic Peak PG (mmHg)†† | 52 ± 18 | 30 ± 13*** | 52 ± 16 | 22 ± 13*** | 0.072 |
| Aortic Regurgitant Fraction (%) | 19 ± 16 | 10 ± 11* | 16 ± 11 | 9 ± 7** | 0.936 |
| MR fraction (%) | 20 ± 18 | 8 ± 10** | 26 ± 16 | 16 ± 16** | 0.514 |
| Left Ventricle | |||||
| EDVI (ml/m2) | 94 ± 25 | 76 ± 13*** | 94 ± 21 | 88 ± 20** | 0.023 |
| LVEF (%) | 58 ± 12 | 61 ± 11* | 52 ± 11 | 54 ± 11 | 0.403 |
| Mass Index (g/m2) | 76 ± 22 | 61 ± 16*** | 79 ± 21 | 66 ± 18*** | 0.691 |
| LVM/LVEDV (g/ml) | 0.82 ± 0.2 | 0.81 ± 0.2 | 0.86 ± 0.2 | 0.77 ± 0.2*** | 0.041 |
| Peak Circumferential strain | |||||
| Base (%) | −19.8 ± 5.2 | −18.6 ± 4.9 | −17.6 ± 5.8 | −18.5 ± 5.8 | 0.03 |
| Mid (%) | −21.1 ± 5.3 | −20.0 ± 4.3 | −19.3 ± 6.1 | −19.8 ± 6.5 | 0.158 |
| Apex (%) | −20.0 ± 6.4 | −17.5 ± 6.8** | −18.8 ± 6.7 | −18.8 ± 6.0 | 0.054 |
| Peak mid-ventricular strain rate | |||||
| Systolic (S−1) | −0.032 ± 0.010 | −0.034 ± 0.009 | −0.029 ± 0.008 | −0.032 ± 0.007** | 0.188 |
| Diastolic (S−1) | 0.028 ± 0.016 | 0.028 ± 0.018 | 0.022 ± 0.015 | 0.023 ± 0.014 | 0.653 |
| LV torsion | 14.08 ± 8.40 | 7.81 ± 4.51*** | 14.43 ± 4.66 | 11.20 ± 4.62*** | 0.094 |
| LV twist (°) | 16.17 ± 7.01 | 12.45 ± 4.78** | 16.08 ± 5.36 | 12.36 ± 5.21*** | 0.999 |
†Independent samples t-test to compare degree of change seen following SAVR with that seen following TAVI. Paired t test of baseline Vs 6 months: *p < 0.05, **p < 0.01, ***p < 0.001
Fig. 2Change in twist and mid-LV circumferential strain. Twist pre and post-SAVR (a) and pre and post-TAVI (b). Circumferential strain pre and post-SAVR (c) and pre and post-TAVI (d)
Comparison of 6 month strain values following SAVR and TAVI with those from a healthy control group
| Control (n = 5) | SAVR 6 m (n = 46) | p Value | TAVI 6 m (n = 52) | p Value | |
|---|---|---|---|---|---|
| Age (years) | 72.6 ± 1.7 | 73.0 ± 7.0 | 0.769 | 80.9 ± 6.4 | 0.001 |
| LVEF (%) | 62.1 ± 6.0 | 61.1 ± 10.7 | 0.847 | 53.8 ± 10.5 | 0.092 |
| LVMI (g/m2) | 38.0 ± 7.1 | 60.8 ± 15.8 | 0.003 | 66.4 ± 17.9 | 0.001 |
| LV torsion | 12.58 ± 2.12 | 8.09 ± 4.85 | 0.047 | 11.20 ± 4.62 | 0.515 |
| LV twist (°) | 14.24 ± 2.58 | 12.68 ± 4.96 | 0.495 | 12.36 ± 5.21 | 0.432 |
Cox proportional hazard analysis for prediction of all-cause death following valve intervention
| Variable | Univariate analysis | Multivariate analyisis | ||
|---|---|---|---|---|
| Hazard ratio (95% CI) | p-Value | Hazard ratio (95% CI) | p-Value | |
| Age (per year) | 1.125 (1.043–1.215) | 0.002 | 1.084 (0.935–1.256) | 0.286 |
| STS score (per %) | 1.238 (1.037–1.477) | 0.018 | 1.365 (0.943–1.976) | 0.099 |
| eGFR (per ml/min/1.73 m2) | 0.963 (0.936–0.991) | 0.010 | 0.988 (0.947–1.053) | 0.953 |
| Baseline Mid LV CS (per %) | 1.016 (1.007–1.024) | 0.001 | 1.029 (1.007–1.052) | 0.009 |
| Baseline LVEF (per %) | 0.962 (0.926–0.999) | 0.046 | 1.031 (0.949–1.119) | 0.473 |
| TAVI procedure | 3.776 (1.283–11.109) | 0.016 | 0.397 (0.043–3.646) | 0.414 |
| Myocardial Fibrosis (LGE + ve) | 1.670 (0.615–4.541) | 0.315 | - | - |
| Baseline LVMI | 1.014 (0.993–1.035) | 0.189 | - | - |
| History of MI | 0.611 (0.148–2.516) | 0.495 | - | - |
| Mean Aortic PG | 1.018 (0.91–1.046) | 0.182 | - | - |
| Indexed LA volume | 1.012 (0.982–1.043) | 0.428 | - | - |
| LV mass:volume ratio | 8.051 (0.332–195.380) | 0.200 | - | - |
| Zva | 1.788 (0.847–3.778) | 0.128 | - | - |
| BMI | 1.211 (0.990–1.482) | 0.062 | - | - |
| Diabetes Mellitus | 1.119 (0.162–7.744) | 0.909 | - | - |
| Hyperlipidaemia | 1.795 (0.396–8.138) | 0.448 | - | - |
| Hypertension | 0.578 (0.112–2.994) | 0.514 | - | - |
| Previous MI | 0.960 (0.136–6.778) | 0.967 | - | - |
| Previous PCI | 0.733 (0.101–5.305) | 0.758 | - | - |
| Previous CABG | 0.243 (0.043–1.385) | 0.111 | - | - |
| Atrial Fibrillation | 0.980 (0.144–6.673) | 0.984 | - | - |
| Stroke/TIA | 0.742 (0.069–7.960) | 0.805 | - | - |
| Peripheral Vascular Disease | 1.589 (0.145–17.400) | 0.705 | - | - |
| COPD | 0.907 (0.125–6.586) | 0.924 | - | - |
| Pulmonary Hypertension | 0.692 (0.112–4.267) | 0.692 | - | - |
Fig. 3a ROC curve for baseline mid LV circumferential strain showing optimal discrimination value (−18.69%) and an AUC of 0.74. b Kaplan-Meier survival curves for AS patients undergoing valve intervention stratified by mid LV circumferential strain more positive than −18.7% (n = 67, green) or more negative than −18.7% (n = 40, blue). AUC: area under curve, CI: confidence interval